Krebs Biochemicals & (Small Cap) Share Target 2025, 2026 To 2035
|
Krebs Biochemicals & Industries Limited |
|||
|
Price: ₹75.93 (-0.47%) | ||
| 52 Week Low: ₹61.00 52 Week High: ₹129.07 |
|||
| Market Capital: 183.65 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Krebs Biochemicals & Share Price Target For 2025
- 1.1.1: Krebs Biochemicals & Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Krebs Biochemicals & Share Price Target For 2026
- 1.2.1: Krebs Biochemicals & Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Krebs Biochemicals & Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Krebs Biochemicals & Brief Company Overview
- 4: Krebs Biochemicals & Financial Performance
- 4.0.1: Is Krebs Biochemicals & A Good Buy For Long Term?
Krebs Biochemicals &, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 22.5% returns in 1-year showing 21.8% quarterly revenue growth.
To predict the Krebs Biochemicals &'s future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Krebs Biochemicals & Share Price Target For 2025
The line chart displays the monthly closing prices of Krebs Biochemicals & with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Krebs Biochemicals & shares in 2025, see the table below.
Krebs Biochemicals & Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 87.27 (+14.93%) | Price Action: Nov 2018 Low |
| 2025 Target 2 | 86.35 (+13.72%) | Price Action: Apr 2021 Low |
| 2025 Target 1 | 85.4 (+12.47%) | Price Action: 10 Nov 2023 High |
| Current Price | 75.93 | Krebs Biochemicals &'s share price as of 16 May 2025 |
| Stop Loss 1 | 71.6 (-5.71%) | Price Action: 04 Apr 2025 Low |
| Stop Loss 2 | 70.88 (-6.66%) | Price Action: Mar 2017 Low |
| Stop Loss 3 | 70.13 (-7.64%) | Price Action: May 2025 Low |
Short-Term Technical Outlook
Current Technical Position: Krebs Biochemicals & is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹75.9 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.74% | 6-month: -27.09% | 1-year: +22.47%
Krebs Biochemicals & Share Price Target For 2026
The line chart displays the monthly closing prices of Krebs Biochemicals & with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Krebs Biochemicals & shares in 2026, see the table below.
Krebs Biochemicals & Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 120.53 (+58.73%) | Fibonacci Extension Level 64.90% |
| 2026 Target 2 | 118.51 (+56.07%) | Price Action: Chart |
| 2026 Target 1 | 117.34 (+54.53%) | Price Action: 26 Nov 2024 High |
| Current Price | 75.93 | Krebs Biochemicals &'s share price as of 16 May 2025 |
| Stop Loss 1 | 65.7 (-13.48%) | Price Action: 17 May 2024 Low |
| Stop Loss 2 | 65.0 (-14.4%) | Price Action: Oct 2023 Low |
| Stop Loss 3 | 64.2 (-15.45%) | Price Action: 18 Mar 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Krebs Biochemicals & is currently trading near its 52-week low of ₹61, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +22.47% | 3-year: -34.46% | 5-year: -2.52%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Krebs Biochemicals & Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹75.93 | ||
| 2025 | ₹121.43 | +59.92% | ₹123.25 |
| 2026 | ₹127.58 | +5.06% | ₹129.49 |
| 2027 | ₹135.20 | +5.97% | ₹137.23 |
| 2028 | ₹157.42 | +16.43% | ₹159.78 |
| 2029 | ₹170.67 | +8.41% | ₹173.23 |
| 2030 | ₹190.69 | +11.73% | ₹193.55 |
| 2031 | ₹207.42 | +8.77% | ₹210.53 |
| 2032 | ₹222.40 | +7.22% | ₹225.74 |
| 2033 | ₹231.26 | +3.98% | ₹234.73 |
| 2034 | ₹237.85 | +2.84% | ₹241.42 |
| 2035 | ₹250.12 | +5.15% | ₹253.87 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Krebs Biochemicals & Brief Company Overview
Krebs Biochemicals & Industries Limited: A Trusted Partner in Pharmaceutical Innovation Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited is a leading manufacturer of active pharmaceutical ingredients (APIs) catering to the...
Indian healthcare industry. With over three decades of experience, the company has built a solid reputation for its commitment to quality, innovation, and customer satisfaction. Key Products and Services: Manufacturing and sale of APIs for anti-cholesterol and steroid intermediate applications Development of biotech processes for various industries Contract manufacturing services for large pharmaceutical and multinational companies Diverse Product Range: Krebs boasts a diverse product portfolio that includes: Androstenedione Lovastatin Simvastatin Amlodipine Cetirizine Orlistat Serratiopeptidase Telmisartan Phenylephrine Commitment to Excellence: Krebs is committed to delivering high-quality products that meet stringent regulatory standards. The company's state-of-the-art manufacturing facilities and experienced team of scientists ensure that its APIs meet the highest levels of purity and efficacy. Industry Recognition: Krebs has earned recognition for its contributions to the pharmaceutical industry. The company has received numerous awards and accolades for its innovative products, exceptional customer service, and unwavering commitment to quality.Krebs Biochemicals & Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 183.65 Crore | Market valuation of Krebs Biochemicals &'s shares. |
| Revenue (TTM) | 52.72 Crore | Total revenue generated by Krebs Biochemicals & over the past twelve months. |
| Net Income (TTM) | -19.56 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -29.9% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -37.11% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+21.8% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
-1.63 | Company's total debt divided by total shareholder equity. |
| Total Debt | 193.42 Crore | Sum of Krebs Biochemicals &'s current & long-term financial obligations. |
| Total Cash | 13.74 Lakh | Total amount of liquid funds available to Krebs Biochemicals &. |
| Beta | 0.45 | Beta is less than 1 indicating that the Krebs Biochemicals &'s price is less volatile than the market. |
Is Krebs Biochemicals & A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
